When Empty Threats Work: “Price Negotiation” In White House Budget Spooks Wall Street
This article was originally published in RPM Report
Executive Summary
Investors remain hyper-sensitive to any threat to pricing flexibility for biotech products. The latest over-reaction – to a renewed call for Medicare “price negotiation” – meant missing some of the more meaningful messages coming from Washington about support for innovation.
You may also be interested in...
A New Type of Investor Relations for Biopharma
The biopharma industry is facing strong pressure to justify its pricing practices. And not just from politicians.
A New Type of Investor Relations for Biopharma
The biopharma industry is facing strong pressure to justify its pricing practices. And not just from politicians.
The Campaign Against Drug Pricing: Candidates Can Only Hope Voters React As Strongly As Wall Street
Wall Street remains hypersensitive to threats from Washington or the campaign trail to take action to limit prescription drug pricing. But it is still hard to see why the threat is any greater because the Clinton campaign has a “plan” to address the issue.